This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices. Please stay on topic.
Provectus Pharmaceuticals is developing advanced therapies designed to target and destroy the deadliest cancers – melanoma, liver & breast – while eliminating side effects. The product pipeline
Further clinical trial information is available from the Melanoma Clinical Trial Update page, published literature, and at ClinicalTrials.gov.
-----------------------------------------------------------------------------------------------------------------------------------------------
PV-10 link to video and visual references:
http://www.pvct.com/multimedianews.html
PV-10 Trial Participants Telling Their Own Stories in the News
http://www.pvct.com/pv10-videos.html
May 17, 2007
Professor Peter Hersey, M.D. comments on PV-10 and a patient's response
Professor Peter Hersey, M.D., a professor of oncology at the University of Newcastle and Medical and Research Director of the Newcastle Melanoma Unit, comments on PV-10 and a patient's response.
Video can be viewed here.
http://www.pvct.com/hersey_pv10_video.html?pg=2
This 15-minute clip follows the progress of an 86-year-old man treated with the drug. Prior to his treatment, his melanoma was so unresponsive to the current standard of care, including numerous invasive operations and toxic chemotherapy, that he was given only months to live.
Video can be viewed here.
http://www.pvct.com/hersey_pv10_video.html?pg=5
2008, Charles Dawson, PV10 patient, Australia; Professor John Thompson, Sydney Melanoma Unit
Video can be viewed here
https://www.youtube.com/watch?v=HSjoev_q9Nw
December 16, 2010
Madja Rauh recently traveled to Bethlehem with her daughter Ursa Rauh from Ljubljana, the capital of Slovenia in Europe, to receive a promising, experimental treatment for metastatic melanoma with internationally recognized melanoma investigator Sanjiv Agarwala, MD, Chief of Medical Oncology and Hematology, St. Luke's Hospital & Health Network,Bethlehem, PA
Video can be viewed here.
http://www.slhn.org/News/2010/Slovenian-Woman-Receives-Treatment
http://www.pvct.com/inthenews.html?article=20110725&mode=0
Madja Rauh, PV10 patient, has a Facebook page as of 1/ 2015
http://www.pvct.com/inthenews.html?article=20070321&mode=0
http://www.pvct.com/inthenews.html?article=20110725&mode=0
Madja Rauh, PV-10 patient, has a Facebook page as of January 2015
--------------------------------------------------------------
Contact Info
Our Contact Form
Telephone: +1 (866) 594-5999
Fax: +1 (866) 998-0005
info@pvct.com
Mailing Address:
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA • MAP
Transfer Agent:
(i.e. stockholder records, transfer, change of address, etc.)
Broadridge Corporate Issuer Solutions, Inc.
Laura Skorny
1717 Arch Street, Suite 1300
Philadelphia, PA 19103
E-mail: Laura.Skorny@Broadridge.com
Telephone: +1 (610) 649-7300
Fax: +1 (610) 649-7302
Investor Relations:
Porter, LeVay & Rose, Inc.
Marlon A. Nurse
Seven Penn Plaza
New York, NY 10001
Telephone: 212-564-4700
Fax: 212-244-3075
marlon@plrinvest.com
Media Relations:
Porter, LeVay & Rose, Inc.
Bill Gordon
Seven Penn Plaza
New York, NY 10001
Telephone: 212-564-4700
bill@plrinvest.com
Investment Advisor:
Network 1 Financial Securities
Damon Testaverde
Telephone: +1 (800) 205-8031
----------------------------------------------------------- |
